Home / Cancer and immune system / Tocilizumab
ATC L04AC07 · Immunosuppressants
Tocilizumab shortage
As of 31 Oct 2026, Tocilizumab has a reported shortage in 2 of the 5 countries we track (Italy, Austria), covering 11 products.
Countries2/5
Products11packs or presentations
Short since19 Aug 20242.2 years ago
Earliest return31 Mar 2027company estimate
No return date9products
Main reasonIncreased demand
Timeline
ItalyAustria
Solid bars run from the reported start to today; faded bars show the time left until the expected return. An arrow means no return date was given.
Affected products
| Country | Product | Holder | Since | Expected back | Reason |
|---|---|---|---|---|---|
| IT | TYENNE | FRESENIUS KABI DEUTSCHLAND GMBH | 19 Aug 2024 | not given | Increased demand Elevata richiesta |
| IT | TYENNE | FRESENIUS KABI DEUTSCHLAND GMBH | 29 Aug 2024 | not given | Increased demand Elevata richiesta |
| IT | TYENNE | FRESENIUS KABI DEUTSCHLAND GMBH | 8 May 2026 | not given | Manufacturing problem Problemi produttivi: ridotta disponibilità |
| IT | TYENNE | FRESENIUS KABI DEUTSCHLAND GMBH | 31 Aug 2026 | not given | Manufacturing problem Problemi produttivi |
| AT | Tyenne 162 mg Injektionslösung in einem Fertigpen, 4 Stück limited | Fresenius Kabi Deutschland GmbH | 11 Jun 2026 | not given | Increased demand Erhöhter Mehrbedarf |
| AT | Tyenne 162 mg Injektionslösung in einer Fertigspritze, 4 Stück | Fresenius Kabi Deutschland GmbH | 18 Aug 2026 | not given | Increased demand Erhöhter Mehrbedarf |
| AT | Tyenne 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, 1 Stück limited | Fresenius Kabi Deutschland GmbH | 18 Aug 2026 | not given | Increased demand Erhöhter Mehrbedarf |
| AT | Tyenne 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, 1 Stück limited | Fresenius Kabi Deutschland GmbH | 18 Aug 2026 | not given | Increased demand Erhöhter Mehrbedarf |
| AT | Tyenne 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, 1 Stück limited | Fresenius Kabi Deutschland GmbH | 18 Aug 2026 | not given | Increased demand Erhöhter Mehrbedarf |
| AT | Avtozma 162 mg Injektionslösung in einer Fertigspritze, 4 Stück limited | Celltrion Healthcare Hungary Ltd. | 15 Sep 2026 | 31 Jul 2027 | Increased demand Erhöhter Mehrbedarf |
| AT | Avtozma 162 mg Injektionslösung in einem Fertigpen, 4 Stück limited | Celltrion Healthcare Hungary Ltd. | 22 Sep 2026 | 31 Mar 2027 | Increased demand Erhöhter Mehrbedarf |
"Expected back" is the date the company gave the authority, when it gave one. Ask a pharmacist about alternatives.